CLOSE

Specials

  • March
  • June
  • September
  • Bioanalytical Services
  • Life Science Analytics
  • Life Science Compliance
  • Bioanalytical Services APAC
  • APAC
  • Europe

I agree We use cookies on this website to enhance your user experience. By clicking any link on this page you are giving your consent for us to set cookies. More info

Skip to: Curated Story Group 1
lifesciencesreview
US
APAC
  • Home
  • News
  • Contributors
  • Magazine
  • Conferences
  • Newsletter
  • About

Thank you for Subscribing to Life Science Review Weekly Brief

  • Home
  • News

Recommended picks

Must-Know Biotechnology Trends in 2021

Must-Know Biotechnology Trends in 2021

Top Biotech Developments to Watch for

Top Biotech Developments to Watch for

Using AI to Prevent Adverse Effects of Immunotherapy

Using AI to Prevent Adverse Effects...

Ehave, Inc. Uses Artificial Intelligence And Machine Learning for Big Data Management in Mental Health Care

Ehave, Inc. Uses Artificial...

The Role of Technology in the Biotech Sector

The Role of Technology in the Biotech...

Cyberattacks in Hospitals

Cyberattacks in Hospitals

How AI Can Enhance the Prediction of Immunotherapy

How AI Can Enhance the Prediction of...

How Technology is Reshaping Immunotherapy

How Technology is Reshaping...

Must-Know Biotechnology Trends in 2021

Must-Know Biotechnology Trends in 2021

Top Biotech Developments to Watch for

Top Biotech Developments to Watch for

Using AI to Prevent Adverse Effects of Immunotherapy

Using AI to Prevent Adverse Effects...

Ehave, Inc. Uses Artificial Intelligence And Machine Learning for Big Data Management in Mental Health Care

Ehave, Inc. Uses Artificial...

The Role of Technology in the Biotech Sector

The Role of Technology in the Biotech...

Cyberattacks in Hospitals

Cyberattacks in Hospitals

How AI Can Enhance the Prediction of Immunotherapy

How AI Can Enhance the Prediction of...

How Technology is Reshaping Immunotherapy

How Technology is Reshaping...

Phenomic AI Launches with $6 Million Seed Funding,Targeting the Tumour Stroma, An Unresolved Puzzle in the Cancer

By Life Sciences Review | Sunday, December 06, 2020
Tweet

FREMONT, CA: Phenomic AI, a developer of drug discovery platform(headquartered in Toronto) today has announced the official launch of the company with US $6 million seed financing. The company’s platform uses AI to analyse phenotypes in complex disease models enabling pharmaceutical companies to discover drugs in an easier way. The financing was led by CTI Life Sciences Fund and was joined by AV8 Ventures, Luminous Ventures and Viva Bio Innovator. The company’s CEO Sam Cooper explained that the funding will be used by checking the feasibility or the practical potential of the company’s two lead programs discovered by using AI(Artificial Intelligence) and ML(Machine Learning) platform. 


The company’s two lead programs include antibody drugs that target the tumour stroma, which prevents immunotherapies, such as checkpoint inhibitors, working effectively in solid cancers. The tumour stroma is a very complex barrier to the tumour, which comprises many cell types, such as extracellular matrix and cancer associated fibroblast(CAFs). Checkpoint inhibitors have been a recent revolution in the treatment of cancers, but solid tumours have been excluded from its benefit because of the tumour stroma.


However, Phenomic AI could overcome the challenges involved in understanding how different cells interact in disease states, particularly tumour stroma of solid cancers, “a major unresolved puzzle in cancer”, in the words of Cooper.


By targeting the tumour stroma effectively with therapeutic antibodies, the company aims to activate the immune system in stroma-rich cancero, either directly or in combination with immune checkpoint therapies. It targets CAFs in numerous solid cancers which promotes tumour growth and blocks anti-tumour immune activity. 


Phenomic AI Also announced appointments of Dr Michael(Mike)Bristin, as chief scientific officer, and Nobel Laureate James(Jim)P. Allison, Ph.D and Padmasree(Pam) Sharma,M.D, Ph.D, to the company’s advisory board(SAB). AV8 general partner Ruchitha commented that the Phenomic team has made impressive progress in building their platform to find new drug targets in tumour stroma. She also added that appointment of Mike, Jim and Pam has further highlighted the exceptional advancement of Phenomic.


Weekly Brief

loading
Towards a New World Order
> <
  • Other 2021

    Top Vendors

    Current Issue
  • Other 2020

    Top Vendors

    Current Issue

Read Also

Critical Bioanalytical Challenges of ADCs

Critical Bioanalytical Challenges of ADCs

Must-Know Biotechnology Trends in 2021

Must-Know Biotechnology Trends in 2021

Top Biotech Developments to Watch for

Top Biotech Developments to Watch for

Importance of Biomarkers in Drug Development

Importance of Biomarkers in Drug Development
Using AI to Prevent Adverse Effects of Immunotherapy

Using AI to Prevent Adverse Effects of Immunotherapy

Ehave, Inc. Uses Artificial Intelligence And Machine Learning for Big Data Management in Mental Health Care

Ehave, Inc. Uses Artificial Intelligence And Machine Learning for Big Data Management in Mental Health Care

The Role of Technology in the Biotech Sector

The Role of Technology in the Biotech Sector

Why Partner with Bioanalysis Experts?

Why Partner with Bioanalysis Experts?
Loading...

Copyright © 2021 Life Science Review . All rights reserved. |  Subscribe follow on linkedin

This content is copyright protected

However, if you would like to share the information in this article, you may use the link below:

https://www.lifesciencesreview.com/news/phenomic-ai-launches-with-6-million-seed-fundingtargeting-the-tumour-stroma-an-unresolved-puzzle-in-the-cancer-nwid-194.html